Syneron Bio
Latest round
- Series B
Last raised
- Mar 2026
Total raised
- $250M
Investors
- 15
About Syneron Bio
, trading as Syneron Bio, is a biotechnology company dedicated to developing novel macrocyclic peptide drugs. The company utilizes its unique Synova™ platform technology to build a rich and differentiated pipeline of macrocyclic peptide drugs, providing breakthrough treatment solutions for global oncology, autoimmune diseases, and rare diseases. The company generates revenue by developing and providing novel macrocyclic peptide drugs and other related services.
Who invested in Syneron Bio
15 investors across 2 rounds
See all investors in Syneron Bio
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Syneron Bio
Who invested in Syneron Bio?
Syneron Bio has 15 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Syneron Bio raised?
Syneron Bio has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Syneron Bio last raise money?
Syneron Bio's most recent round on record is a Series B, in Mar 2026.
What does Syneron Bio do?
, trading as Syneron Bio, is a biotechnology company dedicated to developing novel macrocyclic peptide drugs.
Where is Syneron Bio headquartered?
Syneron Bio is headquartered in Beijing, China.
Which VCs invest in companies like Syneron Bio?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Yufu Capital, ICBC Capital Management and Ningbo Tongshang Fund back biotechnology companies at Syneron Bio's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Syneron Bio? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.